Aerosolized Interferon Prophylaxis for Coronavirus Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preventing and inhibiting coronavirus infection, particularly in high-risk populations and areas with high infection rates, are inadequate, leading to ongoing lockdowns and economic disruptions, with existing vaccines and treatments having limitations such as potential side effects and limited immunity duration.

Innovation Solution

Administering aerosolized interferon (Type I, II, or III) via inhalation as a prophylactic measure to individuals at risk, including healthcare workers, students, and those in crowded settings, to activate the mucosal immune system and reduce viral transmission.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If aerosolized interferon is administered to activate mucosal immune system, then protection against coronavirus infection is improved, but device complexity and administration complexity increase

Engineering Contradiction:

Improveprotection against coronavirus infectionVSAvoidadministration complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses aerosolized interferon as an intermediary substance that activates the mucosal immune system to provide protection against coronavirus infection. The interferon acts as a mediator between the administered substance and the immune response, creating a biological defense mechanism without requiring complex monitoring or adjustment systems.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs different types of interferon (Type I, Type II, Type III) with varying parameters to achieve optimal protection. The selection of specific interferon types and their concentrations are adjusted to balance effectiveness with administration simplicity, resolving the contradiction between reliability and complexity.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If aerosolized interferon is administered broadly to reduce viral transmission, then spread of virus is reduced, but loss of time and resource consumption increase

Engineering Contradiction:

Improveviral transmissionVSAvoidtime for administration

Core Design Contradiction:

Object-affected harmful factorsVSLoss of time

Solution Approach 1:

The patent administers aerosolized interferon in advance before coronavirus exposure to activate the mucosal immune system proactively. This preliminary action creates immunity before contact with the virus, reducing the need for reactive measures and minimizing time loss associated with outbreak responses.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent implements periodic administration of aerosolized interferon to maintain protective immunity levels. By administering the interferon at regular intervals, the mucosal immune system remains activated without requiring continuous treatment, thus reducing overall time consumption while maintaining protection against viral transmission.

Inventive Principle:

Principle #19Periodic action

3Reliability

If aerosolized interferon is used as prophylactic measure, then additional layer of defense is provided, but quantity of substance and cost increase

Engineering Contradiction:

Improvelayer of defenseVSAvoidinterferon consumption

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent delivers aerosolized interferon specifically to the mucosal surfaces of the respiratory tract where coronavirus infection occurs. This localized administration concentrates the interferon where it is most needed for defense, rather than distributing it systemically throughout the body, thereby reducing overall substance consumption while maintaining effective protection.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of aerosolized interferon provides an additional layer of defense against coronavirus infection, potentially reducing the spread of the virus and mildening symptoms if infection occurs, allowing for safer resumption of activities and reducing the burden on healthcare systems.

Implementation Method 1

Methodology Applied

Scientific EffectInterferon activation of immune system:

Implementation Method 2

Administering aerosolized interferon (Type I, II, or III) via inhalation

Methodology Applied

Scientific EffectAerosol: Aerosol

Data Source

PatentUS20220040265A1Compositions and methods for preventing and/or inhibiting viral infection and spread

Publication Date: 2022.02.10 PETER G CARROLL

AI summary

Use of an interferon (INF), whether Type I (e.g. interferon-alpha, interferon-beta, etc.), Type II (e.g. interferon-gamma) and/or Type III (e.g. interferon-lamda), for inhibiting and/or preventing coronavirus infection in people, including but not limited to those people at risk of exposure to COVID 19 and/or variants thereof.